Literature DB >> 18509350

5-Azacitidine has limited therapeutic activity in myelofibrosis.

R A Mesa, S Verstovsek, C Rivera, A Pardanani, K Hussein, T Lasho, W Wu, A Tefferi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18509350      PMCID： PMC8721528          DOI： 10.1038/leu.2008.136

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

Review 1.  JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials.

Authors:  A Pardanani
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

2.  Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.

Authors:  A Tefferi; T L Lasho; R A Mesa; A Pardanani; R P Ketterling; C A Hanson
Journal:  Leukemia       Date:  2007-04-26       Impact factor: 11.528

3.  Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

Authors:  Ayalew Tefferi; Jorge Cortes; Srdan Verstovsek; Ruben A Mesa; Deborah Thomas; Terra L Lasho; William J Hogan; Mark R Litzow; Jacob B Allred; Dan Jones; Catriona Byrne; Jerome B Zeldis; Rhett P Ketterling; Rebecca F McClure; Francis Giles; Hagop M Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

4.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

Review 5.  International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

Authors:  Ayalew Tefferi; Giovanni Barosi; Ruben A Mesa; Francisco Cervantes; H Joachim Deeg; John T Reilly; Srdan Verstovsek; Brigitte Dupriez; Richard T Silver; Olatoyosi Odenike; Jorge Cortes; Martha Wadleigh; Lawrence A Solberg; John K Camoriano; Heinz Gisslinger; Pierre Noel; Juergen Thiele; James W Vardiman; Ronald Hoffman; Nicholas C P Cross; D Gary Gilliland; Hagop Kantarjian
Journal:  Blood       Date:  2006-05-04       Impact factor: 22.113

6.  A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

Authors:  A Quintás-Cardama; W Tong; H Kantarjian; D Thomas; F Ravandi; S Kornblau; T Manshouri; J E Cortes; G Garcia-Manero; S Verstovsek
Journal:  Leukemia       Date:  2008-04-03       Impact factor: 11.528

7.  New and old treatment modalities in primary myelofibrosis.

Authors:  Francisco Cervantes; Ruben Mesa; Giovanni Barosi
Journal:  Cancer J       Date:  2007 Nov-Dec       Impact factor: 3.360

Review 8.  Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.

Authors:  Ross L Levine; Animesh Pardanani; Ayalew Tefferi; D Gary Gilliland
Journal:  Nat Rev Cancer       Date:  2007-09       Impact factor: 60.716

9.  A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.

Authors:  R A Mesa; J K Camoriano; S M Geyer; W Wu; S H Kaufmann; C E Rivera; C Erlichman; J Wright; A Pardanani; T Lasho; C Finke; C Y Li; A Tefferi
Journal:  Leukemia       Date:  2007-06-21       Impact factor: 11.528

10.  TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.

Authors:  T L Lasho; A Tefferi; J D Hood; S Verstovsek; D G Gilliland; A Pardanani
Journal:  Leukemia       Date:  2008-03-20       Impact factor: 11.528
View more
  15 in total

Review 1.  New drugs for the treatment of myelofibrosis.

Authors:  Ruben A Mesa
Journal:  Curr Hematol Malig Rep       Date:  2010-01       Impact factor: 3.952

Review 2.  Management of myeloproliferative neoplasms: from academic guidelines to clinical practice.

Authors:  Giovanni Barosi; Letizia Lupo; Vittorio Rosti
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

3.  Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.

Authors:  Kiran Naqvi; Naval Daver; Naveen Pemmaraju; Prithviraj Bose; Guillermo Garcia-Manero; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2016-08-05

Review 4.  Novel therapies for myelofibrosis.

Authors:  Brady L Stein; Francisco Cervantes; Francis Giles; Claire N Harrison; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2015-05-18

Review 5.  Novel Therapies for Myelofibrosis.

Authors:  Kristen Pettit; Olatoyosi Odenike
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

6.  Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.

Authors:  Claire Harrison; Alessandro M Vannucchi
Journal:  Ther Adv Hematol       Date:  2012-12

Review 7.  New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.

Authors:  Ami B Patel; Nadeem A Vellore; Michael W Deininger
Journal:  Clin Cancer Res       Date:  2016-03-01       Impact factor: 12.531

Review 8.  Novel myelofibrosis treatment strategies: potential partners for combination therapies.

Authors:  B L Stein; R Swords; A Hochhaus; F Giles
Journal:  Leukemia       Date:  2014-06-03       Impact factor: 11.528

9.  A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.

Authors:  Lucia Masarova; Srdan Verstovsek; Juliana E Hidalgo-Lopez; Naveen Pemmaraju; Prithviraj Bose; Zeev Estrov; Elias J Jabbour; Farhad Ravandi-Kashani; Koichi Takahashi; Jorge E Cortes; Jing Ning; Maro Ohanian; Yesid Alvarado; Lingsha Zhou; Sherry Pierce; Romany Gergis; Keyur P Patel; Rajyalakshmi Luthra; Tapan M Kadia; Courtney D DiNardo; Gautam Borthakur; Kapil Bhalla; Guillermo Garcia-Manero; Carlos E Bueso-Ramos; Hagop M Kantarjian; Naval Daver
Journal:  Blood       Date:  2018-09-05       Impact factor: 22.113

10.  Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms.

Authors:  Paola Guglielmelli; Alessandro M Vannucchi
Journal:  F1000 Med Rep       Date:  2010-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.